Longitudinal Blood-Based Biomarkers and Clinical Progression in Subjective Cognitive Decline
This cohort study of individuals with SCD suggests that longitudinal plasma pTau217 and GFAP are suitable biomarkers for monitoring AD pathology. Their changes were associated with cognitive decline and clinical progression, supporting their potential utility for early intervention and disease monitoring.
Authors
- Calvin Trieu (ORCID: https://orcid.org/0000-0001-6266-2198)
- Argonde C. van Harten (ORCID: https://orcid.org/0000-0002-1477-8724)
- Wiesje M. van der Flier (ORCID: https://orcid.org/0000-0001-8766-6224)
- Lynn Boonkamp (ORCID: https://orcid.org/0000-0002-2200-0832)
- Elsmarieke van de Giessen
- Mardou S. S. A. van Leeuwenstijn
- Inge M.W. Verberk (ORCID: https://orcid.org/0000-0003-0341-7445)
- Sietske A.M. Sikkes (ORCID: https://orcid.org/0000-0002-0161-3656)
- Charlotte Elisabeth Teunissen (ORCID: https://orcid.org/0000-0002-4061-0837)
- Lisa‐Marie Schlüter
- Azzam Aladdin
Institutions
- Amsterdam Neuroscience (NL)
- Amsterdam University Medical Centers (NL)
- Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-12-03
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.45862
- Citations
- 3
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 4.41
Funders
- Eli Lilly and Company
- Biogen
- EU Joint Programme – Neurodegenerative Disease Research
- Prothena
- Health~Holland
- Noaber Foundation
- Roche Nederland
- Amsterdam University Medical Centers
- European Commission
- ZonMw
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- Eisai
- Hersenstichting
- Stichting Dioraphte
- Alzheimer Nederland
- Amsterdam Neuroscience
- GIESKES-STRIJBIS FONDS
- HORIZON EUROPE Framework Programme